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Peptide-siRNA nanocomplexes targeting NF-κB
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Samuel A. Wickline,2 and Christine T.N. Pham1
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1

The NF-κB signaling pathway is implicated in various inflammatory diseases, including rheumatoid arthritis (RA); therefore,
inhibition of this pathway has the potential to ameliorate an array of inflammatory diseases. Given that NF-κB signaling
is critical for many immune cell functions, systemic blockade of this pathway may lead to detrimental side effects. siRNAs
coupled with a safe and effective delivery nanoplatform may afford the specificity lacking in systemic administration of
small-molecule inhibitors. Here we demonstrated that a melittin-derived cationic amphipathic peptide combined with siRNA
targeting the p65 subunit of NF-κB (p5RHH-p65) noncovalently self-assemble into stable nanocomplexes that home to
the inflamed joints in a murine model of RA. Specifically, administration of p5RHH-p65 siRNA nanocomplexes abrogated
inflammatory cytokine expression and cellular influx into the joints, protected against bone erosions, and preserved
cartilage integrity. The p5RHH-p65 siRNA nanocomplexes potently suppressed early inflammatory arthritis without
affecting p65 expression in off-target organs or eliciting a humoral response after serial injections. These data suggest that
this self-assembling, largely nontoxic platform may have broad utility for the specific delivery of siRNA to target and limit
inflammatory processes for the treatment of a variety of diseases.

Introduction

The NF-κB family consists of 5 members: RelA (also known as
p65), Rel (also known as c-Rel), RelB, p105 (processed to p50),
and p100 (processed to p52) (1). These members form homo- and
heterodimers that, in the resting cell, are normally held inactive
in the cytoplasm by association with inhibitors, the IκB proteins.
Activation of NF-κB is controlled by the IκB kinase (IKK) complex that phosphorylates IκB proteins and targets them for degradation, releasing the NF-κB subunits for nuclear translocation
and transactivation of a multitude of responsive genes, including
several inflammatory cytokines. Thus, the NF-κB pathway plays
a crucial role in the inflammatory response of macrophages and
lymphocytes in many inflammatory diseases.
Rheumatoid arthritis (RA) is a chronic and debilitating inflammatory arthropathy. Although the etiology of RA remains controversial, the hallmark of the disease is characterized by inflammation of the synovial lining of diarthrodial joints, massive synovial
proliferation, and an influx of inflammatory cells, macrophages,
and lymphocytes through leaky angiogenic blood vessels (2–4).
This cellular influx and synovial proliferation lead to the release
of inflammatory cytokines and matrix-degrading enzymes, all of
which contribute to the destruction of connective tissue, cartilage,
and subchondral bone of the affected joints. Activated macrophages and lymphocytes are thus considered principal targets for
therapy in RA. Recent understanding of inflammatory responses
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in RA has led to the development of several effective treatment
modalities. These include a number of “biologics” aimed at inhibiting the action of several inflammatory cytokines, including IL-1β,
IL-6, and TNF-α (5). Yet despite these advances, many patients
with RA fail to respond to these new biologic agents. Moreover,
studies have shown that around half of the initial responders eventually stop responding in the first year due to inefficacy or have
to stop therapy altogether due to side effects (6). Although other
biologic therapies, such as the JAK kinase inhibitor tofacitinib, are
beginning to emerge (7), the complexity of RA, the heterogeneity
of patients, and previous experience with biologics suggest that
targeting a single receptor or cytokine pathway will not lead to a
predictable response in patients.
We reasoned that the simultaneous interruption of several
inflammatory cytokine pathways would lead to a higher likelihood
of abrogating disease progression and promoting disease remission. The role of NF-κB in inflammation in general and RA in particular as a central checkpoint is well established (8–11). Accordingly, in the present work, we sought to define the utility of a
novel siRNA delivery approach using nanoparticles targeted to the
NF-κB signaling subunit p65, which is a principal transcriptional
regulator of the canonical NF-κB pathway (12). The nanoparticle
construct is composed of a self-assembling peptide-siRNA complex that serves to protect the siRNA from serum deactivation,
while avoiding reticuloendothelial system uptake and delivering
functional oligonucleotides to selected inflammatory targets (13,
14). Key features of the complex that promote sequentially coordinated endosomal uptake, endosomal lysis, and siRNA release
depend on specific molecular features of the carrier peptide (13),
which is derived through modification of the bee venom peptide melittin (15). Selected amino acid truncations and substitujci.org   Volume 124   Number 10   October 2014
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Figure 1. p5RHH siRNA nanoparticles accumulate in inflamed paws. Day 4 arthritic
mice received i.v. injection of HBSS, free
Cy5.5-labeled scrambled siRNA (Free siRNA),
p5RHH-Cy5.5–labeled scrambled siRNA
nanoparticles (p5RHH NP), and in vivo fluorescent images were acquired over time. (A)
Fluorescent signals were readily detected in
the inflamed paws of arthritic mice injected
with free Cy5.5 siRNA and p5RHH siRNA
nanoparticles, but not HBSS. Note the substantially higher level of fluorescence in the
p5RHH siRNA nanoparticle–injected animal
at 7 hours. (B) Organs and blood were collected 2 hours after injection for fluorescence
imaging. The highest signals were detected
mainly in kidneys, while uptake in the
reticuloendothelial system (liver and spleen)
was markedly lower. Note that p5RHH siRNA
nanoparticles were largely cleared from the
circulatory system (blood) 2 hours after
injection (far right). Pseudocolor “efficiency
image” was used to illustrate the organ
accumulation of Cy5.5-labeled siRNA.

tions mitigate the undesirable pore-forming capacity of peptide,
yet retain its ability to condense siRNA and facilitate endosomal
escape, as previously reported (13, 16). A simple mixing procedure of only 10 minutes yields a complex that is small enough
(~55 nm) to passively diffuse rapidly into inflamed tissues, where
it is retained, yet avoids hepatic sequestration (14). Using a mouse
model of antibody-mediated inflammatory arthritis, we found
that anti–NF-κB peptide-siRNA self-assembling nanocomplexes
(13, 14) effectively silenced the expression of p65 as well as a broad
array of downstream cytokine effectors in the inflamed paws, and
also suppressed arthritis with minimal off-target molecular effects.

Results

p5RHH siRNA nanocomplexes localize to the inflamed joints. Collagen-induced arthritis (CIA) in mice is an experimental arthritis model that in many ways resembles RA. Immunization of
susceptible strains of mice with chick or bovine type II collagen
(CII) leads to the development of anti-CII antibodies that initiate
polyarticular arthritis (17, 18). Transfer of a combination of antiCII monoclonal antibodies derived from mice with CIA also leads
to a severe arthritis accompanied by bone erosion and cartilage
destruction (19). In this CII antibody–induced arthritis (CAIA)
model, we injected 6- to 8-week-old male DBA1/J mice i.p. on day
0 with a cocktail of 5 monoclonal anti-CII antibodies (1.5 mg), followed by i.p. injection with LPS (50 μg) on day 3. Arthritis was evident consistently within 24 hours after LPS injection and persisted
for 2–3 weeks. We administered HBSS, free Cy5.5-labeled scrambled siRNA or p5RHH-Cy5.5–labeled scrambled siRNA nano
complexes (referred to herein as p5RHH siRNA nanoparticles) to
arthritic mice on day 4 and followed particle accumulation in vivo
after injection through whole-body fluorescence imaging (IVIS).
Free Cy5.5-labeled scrambled siRNA and p5RHH siRNA nanoparticles both localized to the inflamed joints. However, we detected
a substantially higher level of Cy5.5 fluorescence in the mouse
4364
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injected with p5RHH siRNA nanoparticles (Figure 1A). The signal
remained stable for at least 7 hours after injection, with gradual
decay over time (Supplemental Figure 1; supplemental material
available online with this article; doi:10.1172/JCI75673DS1).
While previous studies have shown that i.v. administered
free siRNAs are cleared from the system within 15 minutes (20),
we found here that Cy5.5-labeled siRNA packaged in the p5RHH
siRNA nanocomplexes were readily detected in the kidneys 2 hours
after injection, and the signals persisted up to 24 hours (Figure 1B
and Supplemental Figure 2), which suggests that siRNAs packaged
in non-albumin-coated nanoparticles had a different clearance
kinetics than free siRNA. In contrast, the spleen and liver — traditional clearance organs for many types of nanoparticles — did not
sequester substantial amounts of particles (Figure 1B). Furthermore, we observed no signal from Cy5.5-labeled free siRNA in any
organ 2 hours after i.v. administration of an equivalent load (Figure
1B), corroborating the rapid clearance and instability of free siRNA
compared with the more stable nanoparticle-formulated siRNA.
Because we detected no significant fluorescent signals associated with peripheral blood or splenic phagocytes (monocytes/
macrophages and neutrophils) after p5RHH siRNA nanoparticle
injection (Supplemental Figures 3–6), it is likely that accumulation of nanoparticles represents direct delivery into the joint
milieu without peripheral monocyte or splenic macrophage
uptake and subsequent recruitment to the site of inflammation.
To further explore this hypothesis, we injected day 6 arthritic
mice with free Cy3-labeled p65 siRNA or Cy3-labeled p5RHHp65 siRNA nanocomplexes and examined synovial tissues for
intracellular particle accumulation. At 2.5 hours after injection,
we observed a number of tissue macrophages, in the immediate
vicinity of blood vessels, that harbored high intracellular levels
of the p5RHH-p65 siRNA nanoparticles (Figure 2). In contrast,
scant intracellular Cy3 signal was visible in paw sections of the
animal injected with free p65 siRNA.
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Figure 2. p5RHH siRNA nanoparticles target synovial
macrophages. Day 6 arthritic mice were injected with p5RHHCy3–labeled p5RHH-p65 siRNA nanoparticles (p65 NP) or free
Cy3-labeled p65 siRNA (free p65). At 2.5 hours, mice were
sacrificed and paws obtained for immunofluorescence study.
In the mouse injected with p5RHH-p65 siRNA nanoparticles,
Cy3 signal (red) colocalized (yellow in merged images) with
synovial macrophages (Mac-3+, green). In contrast, only very low
signal was detected in the synovial macrophages of the mouse
injected with free p65 siRNA. DAPI (blue) stained nuclei. Some
blood vessels (V) are outlined in white. Scale bar: 20 μm.

p5RHH-p65 siRNA nanocomplexes suppress CAIA. CAIA was
induced as above, and on day 4 (24 hours after LPS injection), when
early arthritis was established in all mice, animals were randomly
divided into 3 treatment groups: HBSS control, p5RHH siRNA
complexes, and p5RHH-p65 siRNA nanocomplexes. Nanoparticles were administered i.v. serially on days 4, 5, and 6. Ankle
thickness changes, arthritis score, and percent weight loss were
assessed over a period of 10 days. p5RHH-p65 siRNA nanoparticle treatment rapidly stabilized ankle swelling and significantly
suppressed arthritis score, an effect that persisted until at least day
10 (Figure 3, A–C). Administration of p5RHH siRNA nanocomplexes did not significantly alter arthritis progression compared
with HBSS treatment (Figure 3, A–C). In addition, treatment with
p5RHH-p65 siRNA nanoparticles did not adversely affect the animals’ weight loss beyond that induced by inflammation and LPS
injection (Figure 3D). On day 10, mice that received p5RHH-p65
siRNA nanoparticles showed an approximately 75% reduction in
ankle thickness and 65% reduction in arthritis score compared
with HBSS and p5RHH siRNA controls. Histologic examination of
paws harvested on day 10 revealed that treatment with p5RHHp65 siRNA nanoparticles significantly attenuated the influx of leukocytes to the inflamed paws, protected against bone erosion, and
preserved cartilage integrity (Figure 3, E–H). On the other hand,
we observed no histologic difference between animals treated
with p5RHH siRNA nanoparticles and those injected with HBSS
(Figure 3, E–H). Furthermore, administration of equivalent doses
of free p65 siRNA did not alter arthritis progression or production
of joint-associated inflammatory cytokines (TNF-α, IL-1β, IL-6,
and MCP-1) compared with HBSS injection (Figure 4, A and B).
These results confirmed the superiority of the p5RHH-based plat-

form in delivering p65 siRNA to synovial macrophages
and suppressing their inflammatory responses. While
free p65 siRNA also diffused into inflamed tissues, the
low level of intracellular accumulation was insufficient to
suppress p65 expression (Figure 4C).
In parallel with improved clinical indices and histology, we found that joint-associated inflammatory cytokine production was significantly suppressed in mice
treated with p5RHH-p65 siRNA nanoparticles (Figure
5A). In addition, mRNA and protein expression levels
of p65 were specifically downmodulated in the paws of
these animals, while those of related NF-κB family members (p100, p105, and RelB) were preserved (Figure 5, B
and C). Moreover, we confirmed that p65 expression in
synovial macrophages was decreased at the single-cell
level (Figure 5D), thus corroborating the findings above
that p5RHH-p65 siRNA nanocomplexes targeted macrophages
and suppressed NF-κB–dependent inflammatory response in the
mitigation of clinical arthritis. In contrast, protein levels of p65
and other NF-κB family members in off-target organs such as liver,
spleen, brain, and kidneys were all relatively preserved (Figure 6).
Taken together, these findings provide proof of concept that
p5RHH siRNA nanoparticles targeting the NF-κB p65 subunit
selectively silenced the gene expression in the intended organs
(joints/synovium) and potently suppressed ongoing inflammation
in a robust model of acute inflammatory arthropathy.
In vivo toxicity profile of p5RHH-p65 siRNA nanocomplexes. To
examine the safety of p5RHH-p65 siRNA nanoparticles in vivo,
we first determined their effect on hematologic parameters. Serial
i.v. injections of p5RHH-p65 siRNA nanoparticles did not affect
peripheral wbc counts and differentials, hemoglobin levels, or
platelet counts (Figure 7A). Although the relatively high accumulation of nanoparticles in the kidney (Figure 1B and ref. 14) was suggestive of preferential renal clearance, we observed no deleterious
effects on renal function, as reflected by normal electrolytes and
levels of blood urea nitrogen and creatinine (Figure 7, B and C).
Finally, we detected no changes among treatment groups in liver
function tests (Figure 7D). These results point to a favorable toxicity profile in vivo after multiple doses.
Effects of p5RHH-p65 siRNA nanocomplexes on immune responses. Next we examined the effects of p5RHH-p65 siRNA nanoparticles on immune cell function in nontarget organs. On day 10,
spleens from different treatment groups were harvested, and splenocytes/splenocyte subpopulations were enumerated. We noted a
trend toward higher numbers of total splenocytes in the p5RHHp65 siRNA nanoparticle treatment group, perhaps reflecting less
jci.org   Volume 124   Number 10   October 2014
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Figure 3. p5RHH-p65 siRNA nanotherapy suppresses inflammation in CAIA. CAIA arthritis was induced as detailed in Methods (day 3 LPS injection is indicated). On day 4, mice were randomly divided into 3 treatment groups: HBSS, p5RHH siRNA nanoparticles, and p5RHH-p65 siRNA nanoparticles. Nanoparticles or HBSS were administered i.v. serially on days 4, 5, and 6 (Tx). (A) Representative photographs of day 10 paws from the 3 treatment groups. (B–D)
Change in ankle thickness (B), arthritis score (C), and percent weight loss (D) were chronicled over time. Values are mean ± SEM (n = 6–8 per group). (E) Day
10 paws were harvested, sectioned, and stained with H&E to evaluate for the number of inflammatory cells/erosions and toluidine blue to evaluate for cartilage integrity. Note the intense inflammatory infiltrates in and surrounding the joint space in HBSS- and p5RHH siRNA–treated animals while joint space
in p5RHH-p65 siRNA–treated animals was largely devoid of cellular infiltrates (left). In higher-power images, erosions (asterisks) were noted along the bone
surface in HBSS- and p5RHH siRNA–treated animals (middle). Extensive proteoglycan depletion (arrowheads) was also noted in HBSS- and p5RHH siRNA–
treated animals (right). b, bone; js, joint space. Scale bars: 400 μm (left), 100 μm (middle), 50 μm (right). (F–H) Inflammatory infiltrates per high-power field
(HPF; F), erosions (G), and degree of proteoglycan depletion (H) were quantified as detailed in Methods. *P < 0.05, **P < 0.01, ***P < 0.001.

cellular efflux from spleen to inflamed sites (joints); however, this
difference did not reach statistical significance (Figure 8A). We
also observed no difference in the composition of the major splenocyte subpopulations, including CD4+ and CD8+ T cells, CD19+
B cells, NK1.1+ natural killer cells, and Foxp3+ T regulatory cells
(Figure 8B). To further assess immune cell function after p5RHHp65 siRNA nanoparticle treatment, we isolated splenic CD4+ T
cells and stimulated them ex vivo on plate-bound anti-CD3 monoclonal antibody. Anti-CD3–activated CD4+ T cells from different
treatment groups proliferated equivalently and released similar
amounts of cytokines (TNF-α, IFN-γ, IL-6, and IL-10; Figure 8,
C–F, and Supplemental Figure 7).
We previously observed that injection of certain types of functionalized nanoparticles can elicit swift complement activation, the
intensity of which depends on the specific type of nanoparticle surface functionalization (21, 22). To assess whether the interaction of
peptide-siRNA nanoparticle complexes with the host complement
system could lead to robust activation, we injected mice with HBSS,
p5RHH siRNA nanoparticles, or p5RHH-p65 siRNA nanoparticles
4366
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and collected their plasma at 30 minutes to quantify the C3 degradation product C3a as evidence of in vivo complement activation
(22). We observed an increase in C3a levels in mice injected with
p5RHH-p65 siRNA nanoparticles compared with HBSS-injected
animals, whereas injection with perfluorocarbon nanoparticles
functionalized with 50 molar percentage of N-[1-(2,3-dioleoyloxy)
propyl]-N,N,N-trimethylammonium methyl-sulfate (DOTAP; ref.
22) generated markedly higher levels of C3a (Figure 9A).
To address the potential immunogenicity of p5RHH siRNA
nanoparticles, we measured specific antibody responses against
both p5RHH peptide and p5RHH siRNA nanocomplexes after 3
serial injections on days 4, 5, and 6. Sera were collected from treated animals on day 10, and IgM and IgG antibodies specific for the
peptide or the nanocomplex were measured by ELISA-based assay
on microtiter plates coated with p5RHH siRNA nanoparticles or
p5RHH-p65 siRNA nanoparticles. No significant difference was
observed among the 3 treatment groups for IgM or IgG responses (Figure 9, B and C). We also measured total antibody levels in
the treated animals and observed no elevation in total IgM or IgG
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Figure 4. Administration of free p65 siRNA does not suppress CAIA. Arthritis was induced as detailed in Methods (day 3 LPS injection is indicated). On
day 4, mice were randomly divided into 2 treatment groups: HBSS and free p65 siRNA. Treatment (Tx) was administered i.v. serially on days 4, 5, and 6. (A)
Changes in ankle thickness, arthritis score, and percent weight loss were chronicled over time. On day 10, animals were sacrificed and paws processed for
(B) cytokine levels and (C) Western blot analysis of p65 and related NF-κB family members (p100, p105, and RelB). p100 and p105 were detected in both
precursor and processed forms (p52 and p50, respectively). No statistical difference between treatments was noted.

levels (Figure 9D). These results suggest that, at the administered
dose and injection schedule, these p5RHH-based nanoparticles
did not elicit systemic adaptive immune responses.

Discussion

Here, we demonstrated that the melittin-derived p5RHH peptides complexed with anti-p65 siRNA successfully and potently
suppress ongoing experimental arthritis. Evidence gathered from
genetic knockout mice suggests a central role for NF-κB, in particular the classical or canonical pathway controlled by p65 or p50,
in RA and other inflammation-related pathologies (1, 8). Because
activation of the canonical pathway results in the transactivation of a number of inflammatory mediators, including TNF-α,
chemokines, and matrix metalloproteases, NF-κB subunit p65
represents an attractive target in RA, especially in instances in
which inhibition of single cytokines proves ineffective. Despite
much interest, small-molecule inhibitor approaches have not
been promising due to lack of specificity (23). Alternatively, gene

silencing might be expected to achieve the specificity that is
lacking in small-molecule inhibitors. When coupled with a safe
and effective delivery nanoplatform, this genetic approach may
circumvent some of the shortcomings of small-molecule inhibitors by specifically suppressing inflammation in the joints, while
largely sparing off-target toxicities.
siRNA-based therapeutics for the treatment of inflammatory
diseases have received increasing attention of late. Several clinical
trials are ongoing for various diseases, including age-related macular degeneration, viral infections, respiratory disorders, and cancer (reviewed in ref. 24). However, the potential use of siRNA therapy in RA has not progressed beyond the preclinical models. These
studies range from local electroporation to deliver siRNA directly
into joint tissue of arthritic mice to several studies of systemic
delivery of liposome- or polymer-based nanoparticles delivering
anti-cytokine or anti-cytokine receptor siRNA (25–30). Although
these preclinical studies all showed efficacy, potential off-target
effects and immune responses were rarely fully addressed.
jci.org   Volume 124   Number 10   October 2014
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Figure 5. p5RHH-p65 siRNA nanoparticles downmodulate inflammatory cytokine production and the expression of p65 specifically in the joints. (A)
Day 10 paws were homogenized, and cleared lysates were assayed for inflammatory cytokines. **P < 0.01, ***P < 0.001. (B) Paws were processed and examined for p65 and p100 mRNA expression relative to Gapdh by real-time PCR. ND, not detected. (C) Paw lysates were probed for the presence of p65, p100,
p105, and RelB by Western blotting. The protein expression of p65 was attenuated in the paw lysates of p5RHH-p65 siRNA nanoparticle–treated animals,
whereas expression of related NF-κB family members was relatively preserved. The analysis was repeated with a second cohort of mice treated with the
same regimen, and similar results were obtained. (D) Day 10 paw sections were probed for macrophages (F4/80+; red) and p65 (green). DAPI (blue) stained
nuclei. Note that p65 protein expression per single cell was decreased in the mouse treated with p5RHH-p65 siRNA nanoparticles. Scale bar: 25 μm.

Cationic lipids and polymers have been successfully used for
in vivo siRNA delivery in preclinical models; however, potential
toxicities (31–33) have hindered the clinical translation of these
platforms. Moreover, these agents tend to aggregate with serum
proteins in vivo and often mediate robust complement activation
with potential deleterious effects (34–36). We recently reported the
development of an amphipathic peptide-based siRNA nanoplatform (13, 14) that uses a modified version of the bee venom component melittin to transport siRNA (15). Melittin is a well-studied
peptide with pore-forming features that derive from its ability to
4368
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insert into lipid membranes stably through hydrophobic interactions among resident membrane phospholipids interacting with its
α-helical peptide secondary structure (16, 37, 38). Subsequent multimeric oligomerization establishes a membrane pore, resulting in
disruption and cell death. Alternatively, apoptosis may be induced
through interactions with intracellular mitochondrial membranes,
depending on membrane cholesterol content (39, 40).
In order to limit the immediate pore-forming potential of
melittin, we initially modified its sequence by selective truncations to produce a shorter amphipathic cationic peptide (termed
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Figure 6. p65 downmodulation is specific to
the inflamed joints. Arthritic mice were serially
treated with HBSS, p5RHH siRNA nanoparticles, or p5RHH-p65 siRNA nanoparticles
on days 4, 5, and 6. Day 10 off-target organs
(spleen, liver, kidney, and brain) were processed,
and protein lysates were probed for expression of p65 and related NF-κB family members
(p100, p105, and RelB) by Western blotting. The
processed forms of p100 and p105 (p52 and p50,
respectively) were only detected in spleen.

p5) that serves well as a “cargo carrier” capable of inserting rapidly into lipid membranes, but is substantially less lytic compared
with native melittin (5,700% decrease; ref. 38). After uptake of the
nanoparticles into endosomes, the residual lytic activity of the p5
peptide enables the disruption of endosomal membrane, allowing the siRNA to escape, as previously shown (14). Further modifications of the peptide sequence were shown to enable numerous other useful attributes, such as protected siRNA transport in
circulation and rapid delivery to target tissues through passive
permeation in addition to endosomal escape after pinocytotic
uptake and concomitant rapid release of siRNA that depends on
endosomal acidification and peptide protonation (13, 14). Avoidance of liver/spleen sequestration and renal clearance also serve
to promote more focused tissue interactions, particularly under
conditions of inflammation and enhanced vascular permeability,
as in cancers (14). Finally, the approach is agnostic as to the exact
oligonucleotide sequence, and the entire complex can be formed
within as little as 10 minutes by a simple mixing procedure that
allows noncovalent self assembly of cationic and anionic moieties
into ~55-nm particles ready for direct injection.
The safety of the system in these short-term applications at
least appears promising for translation, based on the extensive
set of studies we conducted to rule out organ, tissue, and biochemical off-target effects. Initial studies suggested that 3 serial
injections of the nanocomplexes did not elicit a specific humoral
response. However, immunogenicity after repeated dosings of the
nanocomplexes will require further evaluation. These observations also point to a lack of knockdown of normal levels of p65 in
other tissues, in which physiological functioning of NF-κB would
be expected to remain undisturbed, including innate and adaptive T cell–mediated immune responsiveness. The rapid entry into
desired tissue compartments and subsequent prolonged sequestration may initiate through inflamed and leaky vasculature, much
like the endothelial permeability and retention (EPR) effect proposed for nanoparticle cancer localization.
In concert with primary kidney clearance, and given the
advantageous particle sizes for the complex, the potential for

permeation into other normal tissues appears to be minimized.
The avoidance of liver and spleen sequestration and the ability
to maintain normal immune responsiveness elsewhere is a particular advantage of this technology, in contrast to other systems
that might impair immune reactivity (41), with potentially deleterious consequences for cancer surveillance and susceptibility
to infectious diseases. We speculate that the lack of liver/spleen
uptake for these types of nanoparticles may be related to their
immediate acquisition of an albumin coating after injection,
which might be anticipated for any nanosystem in the circulation. Indeed, albumin is known to act both as a particle-stabilizing agent and as a dysopsonin, thereby avoiding liver sequestration (14). Moreover, we have shown previously that an exogenous
albumin coating enhances transfection potential in vitro, which
may offer another advantage for the system after interacting
with serum proteins in vivo (13).
In summary, we have shown that the p5RHH siRNA platform
is a potent and facile delivery system due to its self-assembling
property. The ease with which the siRNA moiety can be switched
out, because it is not chemically conjugated, suggests that its utility can be extended to a number of therapeutic RNA candidates. In
addition to therapeutic applications, the platform may also be used
to interrogate pathway involvement in the pathogenesis of RA and
other inflammatory diseases. Although we took advantage of the
EPR effect to deliver the nanocomplexes in this study, targeting
ligands could be added for enhanced local accumulation or cell
interactions if the need arises. Finally, it is important to point out
that the nanoparticle formulation is critical to the success of the
agent, because even though free siRNA localizes to the intended
site (inflamed joints), it exhibits no gene silencing activity. This is
likely because siRNA packaged as p5RHH nanocomplexes gained
access to the cell cytoplasm through micropinocytosis (14), while
the free siRNA could not. Taken together, our results suggest that
this platform, with its relative site-specific gene silencing activity
combined with minimal off-target toxicities, may have real translational potential for the treatment of many inflammatory processes beyond arthritis.
jci.org   Volume 124   Number 10   October 2014
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Figure 7. In vivo toxicity profile of p5RHH-p65 siRNA nanoparticles. Arthritic mice were serially treated with HBSS, p5RHH siRNA nanoparticles, or
p5RHH-p65 siRNA nanoparticles, on days 4, 5, and 6, and blood was obtained on day 10. (A) Hematologic parameters: wbc counts/differentials, hemoglobin, and platelet counts. (B) Serum electrolytes: sodium, chloride, and potassium. (C and D) Renal (C) and liver (D) function. BUN, blood urea nitrogen.
There was no significant difference noted among the 3 treatment groups.

Methods

Preparation of p5RHH siRNA nanocomplexes. p5RHH peptide (provided
by Genscript) was dissolved at 10 mM in DNAse-, RNAse-, and protease-free sterile purified water (Cellgro) and stored in 10-μl aliquots
at –80°C before use. The Cy5.5-labeled scrambled siRNAs and Cy3labeled p65 siRNAs were ordered from Sigma-Aldrich, dissolved at
100 μM in 1× siRNA buffer (Thermo Scientific), and stored in 10-μl
aliquots at –80°C before use. The p5RHH siRNA nanoparticles were
prepared by mixing equal volumes of the aforementioned p5RHH peptide and siRNA at a peptide/siRNA ratio of 1:20 in HBSS with Ca2+ and
Mg2+ (Gibco, Life Technologies) and incubated on ice for 10 minutes
before injection (14). This preparation typically results in a nominal
nanoparticle size of approximately 55 nm after applying a stabilizing
albumin coating, as measured by atomic force microscopy (14), and
zeta potentials varying from +12 to –5.5 mV and polydispersity index
varying from 0.120 to 0.190 depending on size and the presence or
absence of an exogenously applied albumin coating (13). We also have
previously shown that the uncoated particles are slightly smaller (by
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14%) than the albumin-coated particles by dynamic light scattering
after 40 minutes of mixing the components (13).
Arthritis induction and treatment. All mice were kept in a pathogen-free condition at Washington University Specialized Research
Facility. Arthritis was induced using the collagen antibody–induced
arthritis model (CAIA) with Arthrogen-CIA arthrogenic monoclonal
antibody 5-clone cocktail (Chondrex). 6- to 8-week-old male DBA/1J
mice (Taconic) were injected i.p. with 1.5 mg of the 5-clone antibody
cocktail on day 0 and 50 μg of LPS on day 3. Starting on day 4, when
early arthritis was established, animals received daily serial i.v. injections of p5RHH siRNA nanoparticles, p5RHH-p65 siRNA nanoparticles (1 mg/kg i.v. by tail vein), or an equivalent concentration of free
p65 siRNA for 3 consecutive days. HBSS injection served as the control. Clinical manifestations of arthritis were assessed daily on a scale
of 0–3 (0, no swelling or erythema; 1, slight swelling or erythema; 2,
moderate erythema and swelling in multiple digits or entire paw; 3,
pronounced erythema and swelling of entire paw), with a maximum
score of 12 (3 score × 4 paws) per mouse. Change from baseline in
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Figure 8. Effects of p5RHH-p65 siRNA nanoparticles on off-target immune cells. Arthritic mice
were serially treated with HBSS, p5RHH siRNA
nanoparticles, or p5RHH-p65 siRNA nanoparticles
on days 4, 5, and 6, and spleens were harvested
on day 10. (A) Splenocytes were enumerated upon
harvest at day 10. (B) Splenic immune cell subpopulations were analyzed by flow cytometry using
markers specific for T cells (CD4 and CD8), B cells
(CD19), natural killer cells (NK1.1), and T regulatory
cells (Foxp3). (C–F) Splenic CD4+ T cells (2 × 105)
were purified by magnetic beads and activated ex
vivo on plate-bound anti-CD3 monoclonal antibody
(5 μg/ml) for 72 hours. The supernatants were
harvested and assayed for TNF-α (C), IFN-γ (D),
IL-6 (E), and IL-10 (F) by cytometric bead array. CD4+
T cells cultured in medium without anti-CD3 served
as controls.

paw thickness was determined daily by dial calipers, and an average
change in ankle thickness was determined for each mouse from the
2 hind paw measurements. Mice were also weighed every other day,
and the percentage of weight loss from baseline was calculated. On
day 10, mice were sacrificed, and their blood, paws, and organs were
harvested for analysis.
Histologic analysis. Paws were harvested on day 10, fixed in 10%
buffered formalin for 48 hours, decalcified in EDTA solution, embedded in paraffin, and sectioned at 5 μm. The sections were stained with
H&E or toluidine blue. Inflammatory cell influx, bone erosions, and cartilage integrity were assessed as previously described (42, 43). Digital
images of 5 random areas per H&E-stained paw section were acquired
at ×400 magnification, and the number of exuded inflammatory cells
was enumerated. The number of bone erosions was enumerated per
millimeter of bone surface using ImageJ. Proteoglycan content, an
indication of cartilage integrity, was graded on toluidine blue–stained
sections on a scale of 0–4 (0, fully stained cartilage; 1, <25% unstained;
2, 25%–50% unstained; 3, 50%–75% unstained; 4, >75% unstained), as
previously described (44). Quantitative scoring was performed by an
observer blinded to the treatments. Each value represents the average
per animal derived from the cumulative scoring of 2 hind paws.
Immunofluorescence. The frozen sections (9 μm) of harvested paws
were fixed in 4% paraformaldehyde for 20 minutes at room temperature, incubated with rat anti-mouse F4/80 (1:100 dilution; catalog
no. 14-4801, eBioscience), biotinylated rat anti-mouse Mac-3 (1:200
dilution; catalog no. CL8943AP, Cedarlane Laboratories), or rabbit

anti-mouse p65 (1:100 dilution; catalog no. D14E12, Cell Signaling
Technology), followed by incubation with the appropriate secondary
antibody (1:100 dilution; Jackson Immunoresearch Laboratory). All
images were visualized on a Nikon Eclipse microscope and acquired at
the same exposure with QCapture software.
Real-time PCR. Total RNA from mouse paws was isolated using
RNeasy Midi Kit (Qiagen Inc.) as recommended by the manufacturers. 2 μg RNA was used to synthesize cDNA by reverse transcription
using the High Capacity cDNA Reverse Transcriptase kit (Applied
Biosystems, Life Technologies) on a Multigene thermal cycler system
(Labnet International Inc.). The reverse transcription product served
as the template for real-time PCR analysis on a 7500 RT-PCR System (Applied Biosystems) using fluorogenic primers specific for p65
(PPM04224F, Qiagen Inc.), p100 (PPM03204G, Qiagen Inc.), and
GAPDH (4352339E, Applied Biosystems) according to the manufacturer’s recommendations. Total RNA recovered from p5RHH-p65
siRNA nanoparticle–treated mice was approximately 20-fold lower
than controls due to the lack of inflammation/inflammatory cells. Data
are presented as mRNA expression of target gene relative to Gapdh.
Western blot analysis. Ogran or paw lysates were prepared with 1%
NP-40 lysis buffer containing proteinase inhibitor cocktail (SigmaAldrich). Briefly, cells or paws were homogenized, sonicated in the
lysis buffer, and cleared by centrifugation at 18,000 g for 10 minutes
at 4°C. Protein content was quantified and equivalent amount fractionated by SDS-PAGE under reducing conditions. Membranes were
blotted with anti-p65, anti-p100/p52, anti-p105/p50, and anti-RelB
jci.org   Volume 124   Number 10   October 2014
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Figure 9. Effects of p5RHH-p65 siRNA nanoparticles
on immune responses. (A) Naive mice were injected
with 1 dose of HBSS, p5RHH siRNA nanoparticles,
or p5RHH-p65 nanoparticles, and their plasma was
obtained after 30 minutes for C3a assay as evidence
of complement activation. Mice injected with 50 molar
percentage of DOTAP (DOTAP NP) served as positive
controls for robust complement activation. (B and
C) Arthritic mice were serially treated with HBSS,
p5RHH siRNA nanoparticles, or p5RHH-p65 siRNA
nanoparticles on days 4, 5, and 6. On day 10, serum
was obtained and probed for the presence of IgM
and IgG antibodies against p5RHH (B) or the p5RHH
siRNA nanocomplex (C). The levels of specific antibody
response (measured by direct absorbance at 450 nm)
were similar in all 3 treatment groups and minimally
higher than the levels observed in μMT mice that lack
all antibodies. (D) Total serum levels of IgM and IgG
were also unchanged after nanoparticle treatment.

(1:1,000 dilution; catalog no. 4766S, Cell Signaling Technology) and
anti-mouse β-actin (1:500 dilution; catalog no. sc-1615, Santa Cruz
Biotechnology). The blots were washed and incubated with HRPconjugated anti-rabbit IgG (1:2,000, Jackson ImmunoResearch Laboratories). Bands were visualized using a SuperSignal Western Blotting
Kit (Thermo Scientific).
Cytokine analysis. Paws were homogenized in 1 ml PBS, and lysates
were cleared by centrifugation. TNF-α, IL-6, and MCP-1 concentrations
in paw lysates were measured by cytometric bead array using the Mouse
Inflammation Kit (catalog no. 552364, BD Biosciences) according to the
manufacturer’s recommendations. IL-1β was measured by ELISA (R&D
Systems) according to the manufacturer’s recommendations.
Hematologic parameters and serum chemistries. Day 10 blood
was drawn from the inferior vena cava and assayed for wbc counts/
differentials and serum chemistries (hepatic and renal functions).
Analysis was performed by the Washington University Department
of Comparative Medicine.
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Analysis of splenic subpopulations. Spleens were
harvested and mechanically dissociated to obtain
single-cell suspensions. The following antibodies were used: PE-conjugated anti-CD25 (PC61,
BD Biosciences — Pharmingen), PE-conjugated
anti-NK1.1 (PK136, eBioscience), FITC- or PerCPconjugated anti-CD4 (L3T4, BD Biosciences —
Pharmingen), FITC-conjugated anti-CD19 (1D3,
BD Biosciences — Pharmingen), PerCP- or APCconjugated anti-CD8 (53-6.7, BD Biosciences —
Pharmingen). In general, 106 cells were blocked
with the anti-FcR mAb 2.4G2, stained with the indicated Abs for 20 minutes at 4°C, and then washed
and resuspended for FACS analysis. Foxp3 expression was analyzed using the Foxp3 Staining Kit (catalog no. 88-8118-40, eBioscience) according to the
manufacturer’s instructions. Flow cytometry was
performed using a BD FACSCalibur. Data analysis
was performed using BD CellQuest Pro software.
CD4+ T cell purification and stimulation. CD4+
T cells were isolated from mouse spleens with
autoMACS Separator by positive magnetic sorting according to the
manufacturer’s protocol (MACS CD4+ microbeads; catalog no. 130049-201, Miltenyi Biotech). The purity of the isolated CD4+ population
was verified by surface staining with fluorescently labeled anti-CD4,
anti-CD8, and anti-CD19 mAbs (BD Biosciences) and flow cytometry.
Purified CD4+ T cells were resuspended at 2 × 106 cells/ml in RPMI
1640 supplemented with 10% (v/v) FBS, 1% (v/v) NEAA, 1% (v/v)
sodium pyruvate, 2 mM l-glutamine, 10 mM HEPES, 50 μM 2-mercaptoethanol, 100 μg/ml streptomycin, and 100 U/ml penicillin (Sigma-Aldrich), then plated at 2 × 105 cells/well in 96-well flat-bottomed
microtiter plates coated with 5 μg/ml anti-CD3 mAb (BD Biosciences
— Pharmingen) and cultured for 72 hours.
After the 72-hour incubation, culture supernatants were harvested, and cytokine concentrations were determined by BD Cytometric
Bead Array (CBA) (Mouse Inflammation Kit; catalog no. 552364, BD
Biosciences) according to the manufacturer’s protocol. Cells were
harvested and acquired on BD FACSCalibur for 45 seconds. Cell pro-
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liferation was analyzed using BD CellQuest Pro software. All assays
were performed in triplicate.
Immune responses to nanoparticles. Total IgG and IgM were measured using standard ELISA. Briefly, a 96-well plate was coated with
goat anti-mouse IgG (Southern Biotechnology Associates Inc.) or goat
anti-mouse IgM (Southern Biotechnology Associates Inc.) capture antibody (1 μg/ml in PBS) and incubated at 4°C overnight. After washing and
blocking with 1% BSA in PBS, diluted mouse sera (1:40,00–1:400,00
dilution) were added to wells and incubated at room temperature for
1 hour. After further washing, 100 μl HRP-conjugated goat anti-mouse
IgG (Southern Biotechnology Associates Inc.) or goat anti-mouse IgM
(Southern Biotechnology Associates Inc.) antibody (1:3,000 dilution in
1% BSA in PBS) were added to the plate and incubated for 2 hours at
room temperature. After washing, 100 μl peroxide-chromogen solution
(R&D Systems) was added to each well, and color development was read
at 450 nm with a SpectraMax Plus reader (Molecular Devices). Purified
mouse IgG (Jackson ImmunoResearch Laboratories) and IgM (Rockland Immunochemicals) were used to establish the standard curves.
To measure IgM- or IgG-specific response to the p5RHH peptide
or p5RHH siRNA nanocomplexes, 96-well plates (Immunlon 4 HBX;
Thermo Fisher Scientific Inc.) were incubated with 100 μl/well of
p5RHH peptide or p5RHH siRNA nanoparticles at a p5RHH peptide
concentration of 2 μM at 4°C overnight. To determine the amount of
material that bound to the surface of the wells, unbound p5RHH peptide or p5RHH siRNA nanoparticles were measured using a fluorescence spectrofluorometer (Varian Inc.). Since p5RHH contains 1 tryptophan residue, tryptophan fluorescence emission spectra (300–500 nm)
were measured after excitation at 280 nm. Standard curves were generated, and the amounts of unbound materials were calculated against
standard curves. For the p5RHH-coated plate, peptide was used at a
concentration of 2.21 μg/ml. For the p5RHH siRNA–coated plate, the
peptide was used at a concentration of 3.58 μg/ml. After washing and
blocking with 1% BSA in PBS, diluted mouse sera (1:10–1:100 dilution)
were added to wells and incubated for 1 hour at room temperature followed by HRP-conjugated goat anti-mouse IgG (Southern Biotechnology Associates Inc.) or goat anti-mouse IgM (Southern Biotechnology
Associates Inc.) antibody as above. Color development was performed
using peroxide-chromogen solution (R&D Systems) as above. Data are
presented as direct absorbance (OD at 450 nm).
Off-target nanoparticle uptake. Mice were injected i.v. with 200
μl HBSS or Cy3-labeled peptide/scrambled RNA-seq nanoparticles.
Mice were sacrificed after 30 minutes or 2 hours, and both peripheral blood wbcs and splenocytes were obtained at each time point for
analysis of cell-associated Cy3-labeled particles by flow cytometry.
Cells were also stained with Ly6G (neutrophils), Ly6C (monocytes),
TCR-β (T cells), and CD19 (B cells) (all BD Biosciences — Pharmingen) to detect specific colocalization.
Complement activation. Mice were injected i.v. with 200 μl of peptide-siRNA nanoparticles. Blood was collected from the inferior vena
cava at 30 minutes after nanoparticle injection directly into 10-mM
EDTA tubes to prevent further ex vivo complement activation. Fresh
plasma was prepared from collected blood for C3a ELISA. Briefly,
plates were coated overnight at 4°C with rat anti-mouse C3a (4 μg/ml)
monoclonal antibody (BD Biosciences). After blocking with reagent
diluent (1% BSA in PBS) for 1 hour at RT, the plates were washed 3
times with ELISA wash buffer (0.05% [v/v] Tween 20 in PBS) and
incubated with samples (100 μl of same-day, freshly obtained plas-

ma diluted 1:100 in reagent diluent) for 1 hour at room temperature.
Plates were washed 3 times, followed by incubation with biotinylated
anti-mouse C3a (250 ng/ml) for 1 hour at room temperature. Plates
were washed, incubated with streptavidin-peroxidase (400 ng/ml;
Sigma-Aldrich) for 30 minutes, and washed again, after which 100 μl
peroxide-chromogen solution (R&D Systems) was added to each well,
and color development was read at 450 nm with a SpectraMax Plus
reader (Molecular Devices). Mouse recombinant C3a (BD Biosciences) was used to establish the standard curve.
IVIS imaging. In vivo fluorescence images were acquired and analyzed with a Xenogen IVIS Spectrum imaging system (Caliper LifeSciences). During image acquisition, mice were maintained under isoflurane inhalation anesthesia. The settings (excitation, 640 nm; emission,
700 nm; exposure time, 2 s; binning factor, 8; f value, 2; field of view, 12.9)
were used for image acquisitions at various time points after i.v. injection
of nanoparticles containing Cy5.5 fluorophore–labeled scrambled siRNA,
in free form or packaged in nanocomplexes. For the control animals, HBSS
with Ca2+ and Mg2+ was injected i.v., and images were acquired using the
same settings as above. The resultant pseudocolor “efficiency image” was
used to illustrate the paw or organ accumulation of labeled siRNA.
Statistics. Comparisons between groups were performed by
2-tailed, unpaired t test without correction. Grading data were analyzed with χ2 test. Comparisons among multiple groups (≥3) were performed by 1-way ANOVA. Equality of variance assumption was tested,
and Bonferroni’s correction for multiple comparisons was performed.
Normality assumption appeared to be met, and tests for equality variance were conducted, revealing no differences. The sample size chosen (number of animals per treatment) was based on means and variances in similar experiments with various mouse models of arthritis
for detection of differences between experimental groups at an α level
of 0.05 and a statistical power of 0.80, assuming a 2-sided test.
Study approval. All animal experiments were performed in compliance with federal laws and in strict accordance with the guidelines
established by the Division of Comparative Medicine at Washington
University. The animal protocol is subjected to annual review and
approval by The Animal Studies Committee of Washington University.
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